Source: International Congress 2015 – Emerging strategies for airway disease treatments
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Stefen Boehme (San Diego, United States of America), Stefen Boehme, Tai Wei Ly, Kevin Bacon. LATE-BREAKING ABSTRACT: Inhibition of MAP3K19 - A novel therapeutic approach for treatment of IPF. Eur Respir J 2015; 46: Suppl. 59, 4374

Member's Comments

No comment yet.

Related content which might interest you: Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 LATE-BREAKING ABSTRACT: Detrimental effects of medically indicated oral anticoagulation on survival in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – Latest developments in clinical studies in acute and chronic lung diseases Year: 2015 LATE-BREAKING ABSTRACT: Molecular imaging with CXCR4-gallium-68-pentixafor PET correlates with GAP index and treatment effects in idiopathic pulmonary fibrosis Source: International Congress 2016 – Mixed-up imaging of various chest diseases Year: 2016 LATE-BREAKING ABSTRACT: DS102: A bioactive lipid for the treatment of chronic pulmonary disorders Source: International Congress 2016 – Novel mechanisms and therapeutic targets in acute and chronic inflammatory disease Year: 2016 LATE-BREAKING ABSTRACT: Fibroblast conditioned matrix: A new approach to study extracellular matrix (ECM) effects in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – Repair pathways: from lung development to ageing of the lung Year: 2016 LATE-BREAKING ABSTRACT: Antiacid therapy and progression free survival in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – Latest developments in clinical studies in acute and chronic lung diseases Year: 2015 LATE-BREAKING ABSTRACT: Pirfenidone (PFD) effect on morbidity and mortality in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis Year: 2014 Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005 Idiopathic pulmonary fibrosis (IPF): epidemiology, biology, diagnosis and treatment Source: Virtual Congress 2020 – When the lung gets stiff Year: 2020 PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery Source: Eur Respir Rev 2013; 22: 148-152 Year: 2013 Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON Source: International Congress 2016 – IPF treatment II Year: 2016 LATE-BREAKING ABSTRACT: Safety and tolerability of N-acetylcysteine (NAC) with pirfenidone in idiopathic pulmonary fibrosis (IPF): PANORAMA Source: International Congress 2015 – Latest developments in clinical studies in acute and chronic lung diseases Year: 2015 Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment II Year: 2016 Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Source: Eur Respir J 2007; 30: 835-839 Year: 2007 LATE-BREAKING ABSTRACT: Reducing inflammation in the lung by targeting the endothelial cystic fibrosis transmembrane conductance regulator with copper-tobramycin Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology Year: 2014 LATE-BREAKING ABSTRACT: Inhibition of RC kinase is a novel therapeutic approach for the treatment of COPD and IPF Source: International Congress 2014 – Latest insights in airway diseases Year: 2014 PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by inhibition of multiple pro-inflammatory/fibrotic key mediators Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013 Idiopathic pulmonary fibrosis: approaches to diagnostic Source: Eur Respir J 2002; 20: Suppl. 38, 61s Year: 2002